Abstract
INTRODUCTION Docetaxel is one of the most active chemotherapeutic agents against breast cancer [1] . Data from a randomized trial show an increased tumor response with increasing docetaxel dose within a dose range of 60-100 mg/m 2 administered every 3 weeks [1] . In general, the incidence and severity of adverse events increases with docetaxel dose. Previously, docetaxel dose was limited by hematologic toxicities such as febrile neutropenia [2] ; however, their impact has been drastically reduced by the use of granulocyte colony-stimulating factor (GCSF) as prophylaxis. Thus, in recent years, non-hematologic toxicities have become more clinically important. The incidence and severity of a number of non-hematologic toxicities, such as fluid retention (FR), are associated with increasing docetaxel dose [1] .
In our own clinical practice, we have recently experienced many cases of docetaxel-induced hand-foot syndrome (HFS) and facial (cheek) erythema (FE), especially among patients receiving relatively high doses of docetaxel for adjuvant and neoadjuvant chemotherapy.
Corticosteroids administered over 3 days, starting 2 days prior to chemotherapy, have been shown to delay the onset of docetaxel-induced FR. In one study, patients who received methylprednisolone premedication had significantly delayed onset of FR. and received a significantly higher median cumulative dose of docetaxel before the onset of FR [3] . Among patients treated with TAC   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 (docetaxel, doxorubicin, cyclophosphamide) and given corticosteroid premedication (starting 1 day prior to chemotherapy), Suh et al. [4] found that corticosteroid postmedication (three 8 mg doses, b.i.d., until 1 day after chemotherapy) yielded no improvement in the incidence of severe FR on day 2.
Both docetaxel-induced cumulative FR and the means by which corticosteroids delay its onset remain poorly understood. One possible explanation involves induction of the cytochrome P 450 (CYP) system. Clinically relevant doses of dexamethasone (e.g. 8 mg orally two times a day for 5 days),
reportedly increase hepatic cytochrome P 450 3A4 (CYP3A4) activity by an average of 25.7% [5] . Thus, dexamethasone treatment could potentially bring about a clinically significant increase in the clearance of CYP3A4 substrates such as docetaxel.
H 2 blockers, such as cimetidine and ranitidine, are weak inhibitors of CYP3A4 [6] . A single dose of cimetidine (800 mg orally) was found to have a small but significant effect (30% increase) on the area under the concentration-time curve (AUC) of midazolam. Five days of cimetidine treatment (400 mg orally b.i.d.) increased the AUC of epirubicin by 50% (not statistically significant due to a small sample size) [7] . Cimetidine also reportedly affects the pharmacokinetics of 5-fluorouracil (5-FU): pretreatment with cimetidine for 4 weeks led to an increased 5-FU plasma concentration and AUC [8] . For oral 5-FU, the AUC was increased by 72% and for intravenous 5-FU, the AUC was increased by 27% and total body clearance was decreased by 28% [8] .
Although H 2 blocker premedication is not mandatory for docetaxel, it is commonly prescribed   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 in Japan, probably as a result of the common practice of administering H 2 blocker premedication for paclitaxel treatment. Another possible explanation is that clinicians are aiming to minimize the gastrointestinal side effects of dexamethasone, although there is no convincing evidence to support this usage [9] .We hypothesized that H 2 blockers would increase the incidence of docetaxel-induced skin toxicity, given their inhibitory effect on the enzymes that metabolize docetaxel. We also hypothesized that use of steroids prior to chemotherapy would decrease the incidence of these toxicities via the reverse action. In the present retrospective observational study, we aimed to gather data to investigate these hypotheses. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 The following data were collected on a per-institution basis: (1) ranitidine, famotidine and lafutidine, were used. Dexamethasone was the only steroid administered, and all patients in the present study received dexamethasone. The dose of dexamethasone used on days 1 and 2 varied, depending on the chemotherapeutic regimen used and institutional preference, but 8 mg was the most commonly used dose on both days.
PATIENTS AND METHODS
Univariate analysis of factors affecting skin toxicity incidence given that the TX regimen is already known to be associated with a higher incidence of HFS [10, 11] . Use of H 2 blockers significantly increased the incidence of both HFS (OR 2.55, P < 0.001) and FE (OR 3.00,
Lafutidine was associated with a significantly higher OR than the other two H 2 blockers for both HFS (OR 11.73, P < 0.001) and FE (OR 18.48, P < 0.001). There was no general relationship between the dose of steroid on day 1 and/or day 2 and the incidence of either HFS or FE, although there was a small but significantly higher incidence of FE among patients receiving >8 mg of dexamethasone on day 1 compared with those who received ≤8 mg (OR 1.80, P = 0.006).
Cumulative incidence of HFS and FE
The cumulative incidences of HFS and FE are depicted in Figure 1 . Given that most adjuvant and neo-adjuvant docetaxel-based chemotherapy regimens involve four cycles, we investigated cumulative toxicity for cycles 1 and 2, and cycles 3 and after. Grade 2 or higher HFS occurred in 5% of patients in cycle 1, and increased as chemotherapy continued. When an H 2 blocker was used, 20% of patients developed grade 2 or higher HFS by cycles 3 and after. The cumulative incidence of HFS in the absence of an H 2 blocker was about half that seen when an H 2 blocker was used. The incidence of FE was also affected by the use of an H 2 blocker. In the absence of an H 2 blocker, the cumulative incidence of FE by cycles 3 and after was less than a quarter of that seen when an H 2 blocker was used.
Multivariate analysis of factors affecting skin toxicity incidence Tables 3 and 4 show the relationships between steroid (day 1: Table 3 ; day 2: Table 4 ) and H 2 blocker institutional policies, chemotherapy regimen and HFS and FE incidence as determined by multivariate logistic regression analysis. Use of a steroid on days 1 and 2 was a confounding factor, so we performed separate analysis for patients who used steroids on these days.
The two multivariate logistic regression analyses show that use of H 2 blockers significantly increased the incidence of HFS and FE. Lafutidine had the strongest influence on the incidence of both HFS and FE. Ranitidine seemed to have the least influence, although there was still a significant increase in the incidence of FE (OR 2.58; P = 0.029) with day 2 steroid use, and a non-significant increase in FE incidence with day 1 steroid use (OR 2.17; P = 0.101)
Both multivariate analyses showed that the TC regimen was associated with a significantly increased risk of FE but not HFS relative to the other regimens combined. There was no relationship between the dose of dexamethasone given as premedication on day 1 or after chemotherapy on day 2 and the incidence of either HFS or FE .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 65
DISCUSSION
This was a retrospective multi-institutional observational study designed to investigate the correlation between docetaxel-induced skin toxicity and the use of steroids and/or H 2 blockers. We found that H 2 blockers, especially lafutidine, significantly increased the incidence of HFS and FE. The dose of dexamethasone, given either as premedication on day 1 or after chemotherapy on day 2, did not affect the incidence of either HFS or FE. We also found that the TC regimen is associated with a significantly higher risk of FE but not HFS relative to other regimens.
The major limitations of our study are, first, that this is a retrospective analysis, with all the associated drawbacks. Second, the doses and regimens of steroids and H 2 blockers used in our analysis are based on institutional policies rather than individual patients' data. Although we found that lafutidine was associated with a significantly higher incidence of HFS and FE, only one institution used lafutidine, so observer bias may have contributed to this outcome. A further drawback is that pharmacokinetic data from the patients were not available. The best study design to answer the question of whether H 2 blockers increase the incidence of skin toxicity due to increased docetaxel AUC would be a randomized controlled trial, comparing docetaxel with or without H 2 blockers, with HFS and FE incidences as endpoints, and including an analysis of docetaxel pharmacokinetics. However, it would not only be prohibitively
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In vitro studies indicate that CYP3A4 is the major enzyme involved in docetaxel metabolism [12] . Less than 10% of unmetabolized docetaxel is excreted into the feces, and total urinary excretion is also less than 10% [13] . A decrease in total body clearance and an increase in the AUC of docetaxel is associated with increased frequency and severity of side effects [17] . The AUC of docetaxel is reportedly a significant predictor of severe neutropenia, with a 50% decrease in docetaxel clearance corresponding to a 4.3-fold increase in the risk of grade 4 neutropenia and a 3.0-fold increase in the risk of febrile neutropenia [17] .
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A recent study has indicated that skin toxicity occurs in 53% of patients and nail toxicity occurs in 51% of patients receiving docetaxel [18] . Battegay [19] suggested that the antiangiogenic properties of taxanes may be involved in the pathogenesis of nail toxicity. Wasner et al. [20] suggested the existence of a neurogenically mediated inflammatory process. However, little is known about the mechanism underlying drug-induced HFS and FE, except that the two conditions seem to be dose related. In a Japanese study involving a low dose of docetaxel (60 mg/m 2 ), there was a generally low incidence HFS and FE [21] .
In order to decrease the incidence of docetaxel toxicity, especially FR, dexamethasone (8 mg orally b.i.d. for 3 consecutive days starting 24 hours before docetaxel infusion) is often used. This seems to be effective for reducing the incidence and severity of FR [22] , but the effect on skin toxicity is not well understood. In our analysis, the dose of steroid on either day 1 or day 2 had little impact on the incidence of grade 2 or higher HFS and FE. Since most institutions included in this study start dexamethasone therapy just prior to chemotherapy infusion, we were unable to determine whether dexamethasone given the day before chemotherapy has any effect on the incidence of skin toxicity. Since dexamethasone at doses used clinically increases CYP3A4 activity (with extensive inter-subject variability) [5] , an increase in docetaxel clearance might be a factor explaining the lower incidence of FR, although this hypothesis requires confirmation by a well-designed clinical pharmacology study.
For paclitaxel, the incidence of infusion reactions can be reduced by the intravenous Cyclophosphamide, used in the TC regimen, is inactivated by side-chain oxidation mediated by CYP3A4, the same enzyme involved in docetaxel metabolism [26] . This competition might be the one of the mechanisms involved in the increased toxicity of the TC regimen, as observed in the present study.
However, it is difficult to explain why the TC regimen was associated with an increased frequency of FE but not HFS. One possible explanation is that in our analysis the high incidence of HFS in the TX regimen, a non-TC regimen, diminished the difference between TC and combined non-TC regimens, despite the very small number of patients treated using the TX regimen. An alternative explanation is that different mechanisms underlie the occurrence of HFS and FE.
Our retrospective observational study suggests that concurrent use of H 2 receptor antagonists with docetaxel-based regimens may increase the incidence of grade 2 or higher skin toxicities such as FE and HFS, possibly via an inhibitory effect of H 2 receptor antagonists on the CYP3A4-mediated clearance of docetaxel. Also, the TC regimen may increase FE but not HFS. The dose of dexamethasone on days 1 and 2 seems to play no role in skin toxicity.
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